PTC
SRNE

Philadelphia Trust Company’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Philadelphia Trust Company’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-15,600
Closed -$98K – 204
2020
Q2 		$98K Buy
+15,600
New +$59.7K 0.01% 168

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Philadelphia Trust Company's SRNE Position: Q3 2020 in Review

Philadelphia Trust Company sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 15,600 shares — an estimated $98K sold.

Philadelphia Trust Company first reported a position in SRNE in Q2 2020 and held it in 1 quarter. The position peaked at $98K in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Philadelphia Trust Company reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Philadelphia Trust Company sold 15,600 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $98K.
  • Philadelphia Trust Company first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Philadelphia Trust Company's Sorrento Therapeutics, Inc. position peaked at $98K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Philadelphia Trust Company's 13F filing for Q3 2020, filed 12 Nov 2020.